116 related articles for article (PubMed ID: 27070359)
21. Anti-aquaporin-4 immunoglobulin G colorimetric detection by silver nanoparticles.
Higa AM; Moraes AS; Shimizu FM; Bueno RG; Peroni LA; Strixino FT; Sousa NAC; Deffune E; Bovolato ALC; Oliveira ON; Brum DG; Leite FL
Nanomedicine; 2022 Apr; 41():102531. PubMed ID: 35114406
[TBL] [Abstract][Full Text] [Related]
22. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
Sato DK; Nakashima I; Takahashi T; Misu T; Waters P; Kuroda H; Nishiyama S; Suzuki C; Takai Y; Fujihara K; Itoyama Y; Aoki M
Neurology; 2013 Jun; 80(24):2210-6. PubMed ID: 23677744
[TBL] [Abstract][Full Text] [Related]
23. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients.
Ketelslegers IA; Modderman PW; Vennegoor A; Killestein J; Hamann D; Hintzen RQ
Mult Scler; 2011 Dec; 17(12):1527-30. PubMed ID: 21828202
[TBL] [Abstract][Full Text] [Related]
24. Neuromyelitis optica.
Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
[TBL] [Abstract][Full Text] [Related]
25. Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria.
Uzawa A; Mori M; Uchida T; Masuda H; Ohtani R; Kuwabara S
Mult Scler; 2016 Sep; 22(10):1371-5. PubMed ID: 26552730
[TBL] [Abstract][Full Text] [Related]
26. Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders.
Sánchez Gomar I; Díaz Sánchez M; Uclés Sánchez AJ; Casado Chocán JL; Suárez-Luna N; Ramírez-Lorca R; Villadiego J; Toledo-Aral JJ; Echevarría M
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455255
[TBL] [Abstract][Full Text] [Related]
27. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica.
Tasaki A; Shimizu F; Sano Y; Fujisawa M; Takahashi T; Haruki H; Abe M; Koga M; Kanda T
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):419-30. PubMed ID: 24259591
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
[TBL] [Abstract][Full Text] [Related]
29. Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.
Carnero Contentti E; Soto de Castillo I; Daccach Marques V; López PA; Antunes Barreira A; Armas E; de Aquino Cruz C; Rubstein A; Lavigne Moreira C; Molina OM; Soto A; Tkachuk V
Mult Scler Relat Disord; 2018 Feb; 20():109-114. PubMed ID: 29367170
[TBL] [Abstract][Full Text] [Related]
30. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
Huh SY; Min JH; Kim W; Kim SH; Kim HJ; Kim BJ; Kim BJ; Lee KH
Mult Scler; 2014 May; 20(6):695-704. PubMed ID: 24072726
[TBL] [Abstract][Full Text] [Related]
31. Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders.
Dujmovic I; Mader S; Schanda K; Deisenhammer F; Stojsavljevic N; Kostic J; Berger T; Drulovic J; Reindl M
J Neuroimmunol; 2011 May; 234(1-2):124-30. PubMed ID: 21316112
[TBL] [Abstract][Full Text] [Related]
32. Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder.
Sun H; Cui S; Gao F; You Q; Li Y; Wang J; Zhang X
J Neurol Sci; 2018 Jan; 384():91-95. PubMed ID: 29249386
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
[TBL] [Abstract][Full Text] [Related]
34. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
[TBL] [Abstract][Full Text] [Related]
35. Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
Fujihara K; Palace J
Nat Rev Neurol; 2014 Dec; 10(12):679-81. PubMed ID: 25385336
[TBL] [Abstract][Full Text] [Related]
36. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4.
Kim W; Lee JE; Li XF; Kim SH; Han BG; Lee BI; Kim JK; Choi K; Kim HJ
Mult Scler; 2012 May; 18(5):578-86. PubMed ID: 21965418
[TBL] [Abstract][Full Text] [Related]
37. [Clinical concept, etiology and pathology of neuromyelitis optica].
Kurosawa K; Fujihara K
Nihon Rinsho; 2014 Nov; 72(11):1897-902. PubMed ID: 25518368
[TBL] [Abstract][Full Text] [Related]
38. Neuromyelitis optica: not a multiple sclerosis variant.
Barnett MH; Sutton I
Curr Opin Neurol; 2012 Jun; 25(3):215-20. PubMed ID: 22487568
[TBL] [Abstract][Full Text] [Related]
39. Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica.
González C; González-Buitrago JM; Izquierdo G
Clin Chim Acta; 2013 Jan; 415():350-60. PubMed ID: 22580368
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.
Matsuoka T; Matsushita T; Kawano Y; Osoegawa M; Ochi H; Ishizu T; Minohara M; Kikuchi H; Mihara F; Ohyagi Y; Kira J
Brain; 2007 May; 130(Pt 5):1206-23. PubMed ID: 17439988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
